Reduced ex vivo susceptibility of Plasmodium falciparum after oral artemether–lumefantrine treatment in Mali-Reference-Cited by-同舟云学术

Reduced ex vivo susceptibility of Plasmodium falciparum after oral artemether–lumefantrine treatment in Mali

Published:2017-02-02 Issue:1 Volume:16 Page:
ISSN:1475-2875
Container-title:Malaria Journal
language:en
Short-container-title:Malar J

Author:

Dama Souleymane,Niangaly Hamidou,Ouattara Amed,Sagara Issaka,Sissoko Sekou,Traore Oumar Bila,Bamadio Amadou,Dara Niawanlou,Djimde Moussa,Alhousseini Mohamed Lamine,Goita Siaka,Maiga Hamma,Dara Antoine,Doumbo Ogobara K.,Djimde Abdoulaye A.

Funder

European and Developing Countries Clinical Trials Partnership

Wellcome Trust

Medicines for Malaria Venture

International Atomic Energy Agency (AT)

Publisher

Springer Science and Business Media LLC

Subject

Infectious Diseases,Parasitology

Link

http://link.springer.com/content/pdf/10.1186/s12936-017-1700-8.pdf

Reference49 articles.

1. WHO. Guidelines for the treatment of malaria. 2nd ed. Geneva: World Health Organization; 2010.

2. WHO. Global Malaria Programme. World Malaria Report 2014. Geneva: World Health Organization; 2014.

3. WHO. Guidelines for the treatment of malaria. 3rd ed. Geneva: World Health Organization; 2015.

4. Basco LK, Bickii J, Ringwald P. In vitro activity of lumefantrine (benflumetol) against clinical isolates of Plasmodium falciparum in Yaoundé, Cameroon. Antimicrob Agents Chemother. 1998;42:2347–51.

5. Pradines B, Tall A, Fusai T, Spiegel A, Hienne R, Rogier C, et al. In vitro activities of benflumetol against 158 Senegalese isolates of Plasmodium falciparum in comparison with those of standard antimalarial drugs. Antimicrob Agents Chemother. 1999;43:418–20.

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Increase of Plasmodium falciparum parasites carrying lumefantrine-tolerance molecular markers and lack of South East Asian pfk13 artemisinin-resistance mutations in samples collected from 2013 to 2016 in Côte d’Ivoire;Journal of Parasitic Diseases;2024-01-12

2. Increase of Plasmodium falciparum parasites carrying lumefantrine-tolerance molecular markers and lack of South East Asian pfk13 artemisinin-resistance mutations in samples collected from 2013 to 2016 in Côte d'Ivoire;2023-05-30

3. Persistence of Residual Submicroscopic P. falciparum Parasitemia following Treatment of Artemether-Lumefantrine in Ethio-Sudan Border, Western Ethiopia;Antimicrobial Agents and Chemotherapy;2022-09-20

4. Plasmodium falciparum merozoite invasion ligands, linked antimalarial resistance loci and ex vivo responses to antimalarials in The Gambia;Journal of Antimicrobial Chemotherapy;2022-07-29

5. Pyronaridine–artesunate or dihydroartemisinin–piperaquine combined with single low-dose primaquine to prevent Plasmodium falciparum malaria transmission in Ouélessébougou, Mali: a four-arm, single-blind, phase 2/3, randomised trial;The Lancet Microbe;2022-01